Logo of Mesoblast (ASX:MSB)Latest Mesoblast (ASX:MSB) News

Page 1
Page 1 of 5

Healthcare Wrap - Week 44 (26 Oct -> 30 Oct) 2026

Healthcare shares split between clinical progress and cash pressure this week. Mesoblast rose on stronger Ryoncil sales, while several small biotechnology companies fell as investors weighed funding needs and delayed milestones.
Logan Eniac
31 Oct 2026

Mesoblast clears FDA path as Ryoncil revenue rises and pain trial reaches key milestone

Mesoblast has posted a 44% rise in first-quarter Ryoncil revenue to US$28 million while sharply reducing operating cash use. The biotechnology company also completed treatment in its 350-patient chronic low back pain trial and received FDA confirmation that a heart-failure BLA filing may proceed.
Ada Torres
29 Oct 2026

Market Wrap - Week 42 (12 Oct -> 16 Oct) 2026

Small-cap shares swung widely as exploration results, takeover bids and funding needs drove the week’s biggest moves.
Kaoko plunged while PARKD rallied, showing how quickly thinly traded stocks can change direction.
Logan Eniac
17 Oct 2026

Healthcare Wrap - Week 42 (12 Oct -> 16 Oct) 2026

Healthcare shares swung between sharp selling and early commercial progress this week, with EBR Systems falling 40.43% while Firebrick rose 13.79%.
Sales growth, clinical decisions and limited cash reserves remained the key tests for small healthcare companies.
Logan Eniac
17 Oct 2026

Mesoblast Ryoncil revenue jumps 44% as quarterly cash spend falls to US$2.3 million

Mesoblast has reported a sharp first-quarter commercial improvement, with Ryoncil revenue rising 44% and net operating cash spend falling 85% year on year. The company ended September with US$99 million in cash, although the figures remain preliminary.
Victor Sage
16 Oct 2026

Mesoblast turns Ryoncil sales into a commercial launchpad, but profitability remains out of reach

Mesoblast has reported a sharp commercial step-up in FY2026, with Ryoncil generating US$115.2 million in net sales and total revenue reaching US$120.3 million. The company has also completed treatment in its 350-patient back-pain trial and refinanced its debt, but remains loss-making and expects to need more capital beyond the next 12 months.
Ada Torres
12 Oct 2026

Healthcare Wrap - Week 39 (21 Sept -> 25 Sept) 2026

Biotech funding and regulatory setbacks drove the week’s biggest healthcare share moves, while larger companies delivered stronger earnings and deal activity. Telix’s proposed ITM takeover, Ramsay’s demerger plans and a mixed group of clinical updates kept investors focused on cash, approvals and sales.
Logan Eniac
26 Sept 2026

Mesoblast wins FDA clearance for new Ryoncil potency test

Mesoblast has secured FDA approval to add a new potency assay to commercial release and stability testing for Ryoncil, its approved cell therapy for paediatric graft-versus-host disease. The regulatory decision supports tighter monitoring as manufacturing processes evolve, but the company disclosed no direct financial impact or clinical outcome data.
Ada Torres
24 Sept 2026

Healthcare Wrap - Week 34 (17 Aug -> 21 Aug) 2026

Healthcare shares delivered a mixed week, with strong gains at AVITA Medical, Australian Clinical Labs and CSL despite very different company results.
Investors also weighed new US approvals, clinical trial progress, funding needs and rising sales across the sector.
Logan Eniac
22 Aug 2026

Mesoblast Completes Treatment in Pivotal Phase 3 Trial for Chronic Low Back Pain

Mesoblast has treated 350 patients in its pivotal Phase 3 trial for rexlemestrocel-L, targeting chronic low back pain linked to degenerative disc disease, setting the stage for top-line results in mid-2027.
Ada Torres
17 Aug 2026

Healthcare Wrap - Week 31 (27 July -> 31 July) 2026

Xenitra led the healthcare board after a three-year Chinese pharmaceutical deal, while Artrya and InteliCare delivered the week’s biggest contrasting moves. Across the sector, companies raised cash, won regulatory support and pushed deeper into US hospitals and clinics.
Logan Eniac
1 Aug 2026

Mesoblast Posts US$115M Ryoncil Revenue as Adult Trials and CAR Tech Advance

Mesoblast delivered US$115 million in Ryoncil® revenue in its first full year post-FDA approval, while expanding clinical trials into adult indications and acquiring cutting-edge CAR technology to boost its cell therapy pipeline.
Ada Torres
30 July 2026